|
Apr 10
|
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion
|
|
Apr 10
|
Vertex Pharma boosts immunotherapy business in $4.9 billion Alpine Immune deal
|
|
Apr 10
|
UPDATE 2-Vertex Pharma boosts immunotherapy business in $4.9 bln Alpine Immune deal
|
|
Apr 10
|
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
|
|
Apr 10
|
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
|
|
Apr 10
|
Vertex to buy kidney disease drugmaker Alpine for $4.9B
|
|
Apr 9
|
Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
|
|
Apr 1
|
Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
|
|
Mar 28
|
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
|
|
Mar 21
|
Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
|
|
Mar 20
|
Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
|
|
Mar 20
|
Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation
|
|
Mar 19
|
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2023 Earnings Call Transcript
|
|
Mar 19
|
Q4 2023 Alpine Immune Sciences Inc Earnings Call
|
|
Mar 18
|
Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates
|
|
Mar 18
|
Alpine Immune Sciences Inc (ALPN) Reports Full Year 2023 Financial Results
|
|
Mar 18
|
Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
|
|
Mar 14
|
Is a Surprise Coming for Alpine Immune Sciences (ALPN) This Earnings Season?
|
|
Mar 11
|
Adobe (ADBE) to Report Q1 Earnings: What's in the Offing?
|
|
Mar 11
|
Alpine Immune Sciences, Inc. (ALPN) Expected to Beat Earnings Estimates: Should You Buy?
|